16Jun
Diligence Clauses and the Management of Uncertainty in Life Sciences Agreements
In times of uncertainty and disruption, setting expectations for performance with business partners and contractual counterparties can be more complicated than ever. Companies that develop drugs, biologics and medical devices have considerable...
By:
Skadden, Arps, Slate, Meagher & Flom LLP
Related
In celebration of the 100th episode of Corruption Crime and Compliance, Tom Fox, the Compliance Evan...
Read More >
Further developments in relation to harassment - The EAT confirmed in Bessong v Pennine Care NHS Fo...
Read More >
Q. I heard there have been some significant National Labor Relations Board decisions recently. What...
Read More >
Addressing for the first time whether real-parties-in-interest (RPIs) are evaluated at the time a pe...
Read More >
COVID-19’s severe impact on some major metropolitan areas has been attributed to their density, inf...
Read More >
Employers seeking to juggle employee leave demands with their own regulatory compliance obligations ...
Read More >